Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Voyageur Pharmaceuticals Ltd.

Market Cap 20.37M 14.57M 12.6M 11.59M 10.87M 1.39B 20.69M 138M 53.41M 675M 54.77M 53.6M 2.33B P/E Ratio 2024
-5.24x
P/E Ratio 2025 -7.5x
Enterprise Value 20.14M 14.4M 12.45M 11.46M 10.75M 1.38B 20.46M 136M 52.8M 668M 54.15M 52.99M 2.31B EV / Sales 2024
-
EV / Sales 2025 2,423,581,172x
Free-Float
91.6%
Yield 2024 *
-
Yield 2025 -
1 month-81.33%
3 months-88.14%
6 months-86.00%
Current year-89.24%
1 month 0.01
Extreme 0.014
0.08
Current year 0.01
Extreme 0.014
0.13
1 year 0
Extreme 0.0033
0.24
3 years 0
Extreme 0.0005
0.25
5 years 0
Extreme 0.0005
0.25
10 years 0
Extreme 0.0005
0.25
Manager TitleAgeSince
Chief Executive Officer - 2019-06-30
Director of Finance/CFO - 2022-08-16
Chief Tech/Sci/R&D Officer - 2024-09-16
Director TitleAgeSince
Director/Board Member - 2017-12-05
Director/Board Member - 2019-06-30
Chairman - 2025-04-29
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00% - - 16.25M
+2.16%+7.62%+43.83%+160.28% 1,013B
-0.07%+6.76%+52.34%+48.95% 574B
-0.08%+3.52%+18.61%+62.66% 397B
+0.77%+4.97%+21.24%+15.95% 324B
+0.85%+2.79%+24.89%+15.93% 280B
+2.10%+7.06%+24.57%+34.79% 273B
+4.84%+4.68%+20.66%+61.85% 182B
-0.19%+3.96%-45.64%-48.23% 194B
+3.61%-2.42%+14.33%+61.12% 151B
Average +1.56%+2.65%+19.42%+45.92% 376.52B
Weighted average by Cap. +1.61%+3.99%+29.36%+72.50%

Financials

2024 2025
Net sales - 0.01 0.01 0.01 0.01 0.01 0.8 0.01 0.08 0.03 0.39 0.03 0.03 1.34
Net income -1.71M -1.22M -1.06M -971K -911K -117M -1.73M -11.53M -4.48M -56.59M -4.59M -4.49M -196M -3.53M -2.53M -2.18M -2.01M -1.88M -241M -3.59M -23.85M -9.26M -117M -9.5M -9.29M -405M
Net Debt -113K -80.55K -69.64K -64.09K -60.09K -7.7M -114K -760K -295K -3.73M -303K -296K -12.9M -231K -165K -143K -131K -123K -15.76M -234K -1.56M -604K -7.64M -620K -607K -26.41M
Logo Voyageur Pharmaceuticals Ltd.
Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine active pharmaceutical ingredients (API) and imaging contrast agents for medical radiology. It focuses on vertically integrating the barium and iodine contrast markets. In addition, Voyageur is pursuing the development of new endo fullerene drugs. Its products include SmoothX, SmoothHD, SmoothLD, VisionHD, VisionLD and V-Gas. SmoothX (2%w/v) is a contrast medium for use in computed tomography (CT) of the gastrointestinal tract. VisionHD is a high-density (98% w/w) barium powder suspension tailored for double-contrast radiographic examination of the gastrointestinal tract, esophagus, stomach and duodenum. At the core of its operations, the Company also owns a 100% interest in the Frances Creek Project, which boasts a mineral suitable for the pharmaceutical marketplace that is intended to replace the current synthetic products with quality imaging products.
Employees
-
Date Price Change Volume

Annual profits - Rate of surprise

- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!